Composición:
Solicitud:
Usado en tratamiento:
Revisión médica por Militian Inessa Mesropovna Última actualización de farmacia el 23.03.2022
¡Atención! ¡La información en la página es solo para profesionales médicos! ¡La información se recopila en Fuentes abiertas y puede contener errores significativos! ¡Tenga cuidado y vuelva a verificar toda la información de esta página!
Los 20 mejores medicamentos con los mismos ingredientes:
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Simultaneous use of hypolipidemic agents (statins, fibrates), warfarin, beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.